Hematology Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Reagent, By Product, By Region & Competition, 2021-2031F

The Global Hematology Market is projected to expand from USD 18.02 Billion in 2025 to USD 25.41 Billion by 2031, achieving a CAGR of 5.89%. This market encompasses specialized diagnostic instruments, reagents, and consumables utilized by healthcare providers to detect, analyze, and monitor blood disorders. The sector's growth is primarily driven by the rising prevalence of hematologic diseases, such as leukemia and anemia, alongside an aging global population that requires consistent diagnostic oversight. Additionally, the necessity for high-throughput testing in clinical laboratories fuels a steady demand for automated solutions to ensure faster turnaround times for critical patient care.

Underscoring the urgent need for robust diagnostic infrastructure, the 'American Cancer Society' reported in '2025' that 'an estimated combined total of 192,070 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma'. Despite these strong drivers, the market faces a significant obstacle regarding the high capital costs associated with advanced hematology analyzers. This financial burden limits adoption rates among smaller healthcare facilities and within emerging economies, presenting a considerable challenge that could hinder broader market expansion.

Market Driver

The integration of Artificial Intelligence and digital pathology is fundamentally reshaping the Global Hematology Market by optimizing diagnostic precision and workflow efficiency. Laboratories are increasingly implementing AI algorithms that automatically identify and classify blood cells, which significantly reduces the time required for manual microscopic reviews. This technological shift addresses the critical shortage of skilled hematopathologists while minimizing human error in complex diagnoses. Validating this advancement, according to Scopio Labs, July 2025, in a company press release, the firm unveiled its AI-powered Complete Blood Morphology analyzer, a first-of-its-kind solution designed to fully automate the analysis of blood cells and eliminate the need for manual review, rapidly establishing digital hematology as a standard of care.

Simultaneously, the expansion of automated high-throughput hematology analyzers is being propelled by the urgent necessity to manage escalating testing volumes in clinical settings. High-volume laboratories are prioritizing modular automation tracks that integrate hematology with other disciplines to streamline operations and improve turnaround times. This demand is further amplified by the immense global burden of blood disorders; for instance, according to the World Health Organization, August 2025, in the 'WHO global anaemia estimates: key findings, 2025', approximately 30.7% of women aged 15-49 years worldwide suffered from anemia in 2023, necessitating consistent diagnostic monitoring. Reflecting this surge in demand, according to Sysmex Corporation, May 2025, in the 'Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2025', global consolidated net sales increased by 10.2%, driven significantly by higher sales of instruments and reagents in the hematology field.

Market Challenge

The high capital investment required for advanced hematology analyzers constitutes a primary barrier to market growth, particularly in resource-constrained settings. These diagnostic systems, which offer automated and high-throughput capabilities, command premium prices that are often prohibitive for smaller clinics, community health centers, and facilities in emerging economies. Consequently, a significant portion of the potential customer base is unable to transition from manual or semi-automated methods to fully automated solutions, thereby stifling the broader adoption of modern hematology technologies and limiting overall market expansion.

This financial pressure directly impacts purchasing behaviors and procurement cycles within the healthcare sector. Budgetary constraints force many institutions to extend the lifespan of existing equipment rather than investing in newer models. Validating this constraint, according to 'American Hospital Association', in '2025', '94% of health care administrators expect to delay equipment upgrades to manage financial strain'. This widespread deferral of capital equipment acquisition slows the replacement rate of legacy systems and creates a measurable deceleration in revenue generation for manufacturers operating in the global hematology space.

Market Trends

The Global Hematology Market is shifting toward decentralized and point-of-care (POC) testing solutions, driven by the demand for rapid diagnostics in critical care. This trend involves deploying portable analyzers that deliver lab-quality complete blood counts outside traditional laboratories, accelerating clinical decision-making. Manufacturers are actively validating these platforms to meet rigorous regulatory standards. Validating this maturity, according to PixCell Medical, November 2024, in a company press release, its HemoScreen CBC analyzer became the first point-of-care 5-part differential analyzer to achieve certification under the EU's In Vitro Diagnostic Medical Devices Regulation (IVDR), confirming its readiness for diverse healthcare environments.

Concurrently, the rise of personalized hematology diagnostics is transforming blood cancer management by integrating genomic profiling with routine evaluation. Providers are adopting molecular diagnostics to identify genetic mutations, enabling targeted therapies for conditions like acute myeloid leukemia (AML). This approach improves outcomes by tailoring treatment to the disease's biological signature. Highlighting this adoption, according to The Leukemia & Lymphoma Society, November 2024, in the 'Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment' press release, nearly 1,600 patients with AML have received genomic screening within seven days of diagnosis to facilitate precision treatment.

Key Market Players

• Abbott Laboratories Inc.
• F. Hoffmann-La Roche Ltd
• Sysmex Corporation
• Siemens Healthineers AG
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Boule Diagnostics AB
• Nihon Kohden Corporation
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Diatron Medical Instruments Limited

Report Scope

In this report, the Global Hematology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematology Market, By Reagent

• Coagulation Reagents
• Flow Cytometry Reagents
• Immuno-hematology Reagents
• Other

Hematology Market, By Product

• Hematology Analyzers
• Flow Cytometers
• Coagulation Analyzers
• Slide Stainers

Hematology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hematology Market.

Available Customizations:

Global Hematology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).